Misonix To Host BoneScalpel® Spine Workshop At EuroSpine 2015

FARMINGDALE, N.Y., Sept. 2, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), is an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, laparoscopic surgery and other surgical applications.  At the upcoming EuroSpine conference in Copenhagen, Denmark, from September 2-4, 2015, Misonix will be hosting a hands-on workshop entitled "Ultrasonic BoneScalpel Techniques for Treating the Complex Spine."

The ultrasonic BoneScalpel is rapidly being adopted by leading spine surgeons around the globe as they continue to recognize the unique benefits it provides over traditional bone cutting tools.  The device offers a clean, controlled bone incision and removal, while sparing soft tissue structures such as the dura, nerves and arteries. It has been reported to reduce blood loss, cell saver use, blood transfusions and operative time in a variety of spine surgery procedures.

The workshop will demonstrate these benefits along with surgical techniques and tips in many spinal procedures. The Ultrasonic BoneScalpel Techniques for Treating the Complex Spine workshop will be moderated by Daniel Rosenthal, MD, Head of the Spine Section at Hochtaunusklinik in Bad Homburg, Germany. The workshop will review clinical experiences and surgical benefits over traditional technologies.  Dr. Rosenthal commented, "I am looking forward to presenting the BoneScalpel to my colleagues and showing them the additional value it brings to my surgical practice.  My presentation will emphasize that the BoneScalpel enables a safer procedure with minimal blood loss."  

Dr. Rosenthal will be joined at the workshop by Dr. Martin Wilby and Dr. Simon Clark, both consulting neurosurgeons from The Walton Centre in Liverpool, UK.  Dr. Wilby and Dr. Clark will be presenting their clinical experiences and outcome data at the workshop.  Surgeon attendees will have the opportunity to train on the BoneScalpel and participate in detailed discussions with the faculty.

"The BoneScalpel offers a tremendous advantage in complex spine procedures.  It safely incises and removes bone while protecting soft tissue and minimizing blood loss," said Dr. Rosenthal. "The BoneScalpel has changed my surgical practice enabling me to offer my patients a more effective and efficient spinal procedure."

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix comments, "We are excited to attend the EuroSpine 2015 meeting and to have the opportunity to continue to present our BoneScalpel to surgeons and to work with a talented group of European spine surgeons at our Ultrasonic BoneScalpel Techniques for Treating the Complex Spine Workshop.  We are very pleased to see the fast growing adoption rates by high volume spine surgeons from around the world."

EuroSpine (the Congress of the Spine Society of Europe) is an important platform for exchanging the latest research results and innovations in the prevention and treatment of spinal disorders. The aim of the conference is to combine existing knowledge and to develop and implement concepts for the benefit of patients across Europe.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for spine surgery, for wound debridement, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com